.Attribute Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of individuals along with HER2+ advanced bosom cancer cells as well as active or even stable mind metastases showed regular intracranial task as well as systemic efficacy of T-DXd.